Compounds

Patent metadata

Field	Value
Publication number	US-10858367-B2
Application number	US-201816480797-A
Country	US
Kind code	B2
Filing date	Jan 23, 2018
Priority date	Jan 25, 2017
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

First claim

What is claimed is:

1. A compound of Formula (I):

wherein:
R 1 is an N-linked 6-9 membered bridged heterocyclyl ring optionally substituted with one, two or three substituents independently selected from the group consisting of C 3-6 cycloalkyl, C 4-6 heterocyclyl, halo, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl and —CO 2 R 5 ;
wherein:
each C 3-6 cycloalkyl, C 4-6 heterocyclyl, C 1-3 alkyl and C 1-3 alkoxyl as defined for R 1 optionally is substituted with one, two or three substituents independently selected from the group consisting of halo, hydroxyl, unsubstituted C 1-3 alkyl and unsubstituted C 1-3 alkoxyl,
R 5 is selected from the group consisting of H, methyl, NH2, and NHCH3;
provided that:
the C 3-6 cycloalkyl or C 4-6 heterocyclyl substituent is only permitted on a substitutable nitrogen atom of the N-linked 6-9 membered bridged heterocyclyl ring;

R 2 is selected from the group consisting of:
a) 4-7 membered heterocyclyl ring, optionally substituted with one, two or three substituents independently selected from the group of substitutents consisting of
—C 1-3 alkyl, -halo, -hydroxyl, —SO 2 CH 3 , —COCH 3 , and —COCH 2 OH;
wherein:
the —C 1-3 alkyl group is optionally substituted with one, two or three substituents independently selected from the group consisting of: halo, hydroxyl, CO 2 H, —CH 2 CH 2 —, C 1-3 alkoxy and cyano;
wherein:
 when the 4-7 membered heterocyclyl ring contains a substitutable nitrogen atom, the group of substituents defined for the 4-7 membered heterocyclyl ring also includes a 4-6 membered heterocyclyl ring attached to said substitutable nitrogen atom;
wherein,
 the 4-6 membered heterocyclyl ring optionally is substituted with one or two substituents independently selected from the group consisting of cyano, halo, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl, CH 2 OH and C 3-6 cycloalkyl; and
 wherein:
 said C 3-6 cycloalkyl, optionally is substituted with one or two substituents independently selected from the group consisting of halo, hydroxyl, cyano, CH 2 OH, unsubstituted C 1-3 alkyl and unsubstituted C 1-3 alkoxyl;

b) O-linked 4-6 membered heterocyclyl ring, optionally substituted with one or two substituents independently selected from the group consisting of: cyano, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl, CH 2 OH and CO 2 H;
c) C 3-6 cycloalkyl optionally substituted with one or two substituents independently selected from the group consisting of cyano, halo, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl, CO 2 H and a 4-6 membered heterocyclyl ring;
d) O-linked C 3-6 cycloalkyl;
wherein:
the cycloalkyl group is optionally substituted with one or two substituents independently selected from the group consisting of cyano, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl, CH 2 OH and CO 2 H;

e) C 1-6 alkoxy optionally substituted by one or two substituents independently selected from the group consisting of halo, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl, CO 2 H and a 4-6 membered heterocyclyl ring; and
f) C-linked 6-9 membered fused cyclyl ring, optionally having one or two heteroatom ring members independently selected from O and N, optionally substituted with one, two or three substituents independently selected from the group of substituents consisting of —C 1-3 alkyl, -cyano, -halo, -hydroxyl, —SO 2 CH 3 , —COCH 3 , and —COCH 2 OH,
wherein:
which alkyl group is optionally substituted with one, two or three substituents independently selected from the group consisting of: -halo, -hydroxyl, —CO 2 H, —CH 2 CH 2 — and —C 1-3 alkoxy;
when the C-linked 6-9 membered fused cyclyl ring contains a substitutable nitrogen atom, the group of substituents for the C-linked 6-9 membered fused cyclyl ring also includes a 4-6 membered heterocyclyl ring attached to said substitutable nitrogen atom;
wherein:
 the 4-6 membered heterocyclyl ring optionally is substituted with one or two substituents independently selected from the group consisting of cyano, halo, hydroxyl, C 1-3 alkyl, C 1-3 alkoxyl, CH 2 OH and C 3-6 cycloalkyl;
 wherein:
 the C 3-6 cycloalkyl optionally is substituted with one or two substituents independently selected from the group consisting of halo, hydroxyl, cyano, CH 2 OH, unsubstituted C 1-3 alkyl and unsubstituted C 1-3 alkoxyl;

R 3 is selected from the group consisting of halo CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy and C 3-6 cycloalkyl;
R 4 is selected from the group consisting of H, halo, CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy and C 3-6 cycloalkyl; or

a pharmaceutically acceptable salt thereof.

2. The compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:
R 1 is an N-linked 7-9 membered bridged heterocyclyl ring optionally substituted with one substituent selected from the group consisting of oxetanyl, halo, hydroxyl, C 1-3 alkyl, C 1-3 alkoxy and CO 2 R 5 ,
wherein:
R 5 is selected from the group consisting of H, methyl, NH 2 and NHCH 3 ;
provided that:
the oxetanyl substituent is only permitted on a substitutable nitrogen atom.

3. The compound of Formula (I) or a pharmaceutically acceptable salt according to claim 2 , wherein R 1 is an unsubstituted N-linked 7-9 membered bridged heterocyclyl ring.

4. The compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:
R 2 is O-linked C 3-6 cycloalkyl; wherein the cycloalkyl group is optionally substituted with one or two substituents independently selected from the group consisting of cyano, hydroxyl, C 1-3 alkyl, C 1-3 alkoxy, CH 2 OH and CO 2 H.

5. The compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:
R 2 is cyclopropyloxy wherein the cyclopropyl group is optionally substituted with one or two substituents independently selected from the roup consisting of hydroxyl and C 1-3 alkyl.

6. The compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is selected from the group consisting of C 1-3 alkyl and C 1-3 alkoxyl.

7. The compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 4 is selected from the group consisting of H, halo and C 1-3 alkyl.

8. A compound which is

a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable excipient.

10. A method for treating a neurodegenerative disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt according to claim 1 .

11. The method for treating a neurodegenerative disease according to claim 10 , wherein the neurodegenerative disease is Parkinson's disease.

12. The method for treating a neurodegenerative disease according to claim 11 , wherein the subject is a human.

13. The method for treating a neurodegenerative disease according to claim 12 , wherein the subject is a human expressing the G2019S mutation in the LRRK2 kinase.

14. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 8 and a pharmaceutically acceptable excipient.

15. A method for treating a neurodegenerative d

Assignees

• Glaxosmithkline Ip Dev Ltd

Inventors

• Ding Xiao
• Ren Feng
• Sang Yingxia
• Xing Weiqiang
• Zhan Yang
• Zhao Baowei

Classifications

• C07D487/08

  Bridged systems · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D498/08

  Bridged systems · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• A61P25/16 Primary

  Anti-Parkinson drugs · CPC title